Core Viewpoint - Vison Pharmaceutical-B (02561) has seen a significant stock increase of over 12%, currently trading at 35.26 HKD with a transaction volume of 1.9082 million HKD, driven by recent collaboration announcements and strategic partnerships [1] Group 1: Company Developments - Anke Bio recently disclosed progress in its collaboration with Vison Pharmaceutical, indicating that the growth-promoting agent Longpei is nearing approval [1] - On November 6, during the 8th China International Import Expo, Vison Pharmaceutical established a strategic cooperation on dual-chamber freeze-drying technology with leading domestic pharmaceutical equipment company Dongfulong [1] - Vison Pharmaceutical signed an industrial collaboration agreement with the Lingang New Area Management Committee and Lingang Group's trade platform, further advancing its strategy of "Global Innovation, China Acceleration" [1]